Home/Ovid Therapeutics/Jeremy M. Levin, D.Phil, MB BChir
JM

Jeremy M. Levin, D.Phil, MB BChir

Co-founder and Executive Chairman

Ovid Therapeutics

Ovid Therapeutics Pipeline

DrugIndicationPhase
OV329Treatment-resistant seizuresPhase 1
OV350Undisclosed CNS disordersPreclinical
OV882SYNGAP1-related intellectual disabilityResearch
OV4071Undisclosed CNS disordersResearch
Soticlestat (OV935/TAK-935)Dravet Syndrome, Lennox-Gastaut SyndromePhase 3